Zepbound
tirzepatide
APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2023-11-08
US LOE2036-11-01
Peak Sales Est$40000M
Formulations[{"id":"zepbound-sc","doses":"2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg","route":"SC","device":"Pre-fill
Mechanism: GLP-1/GIP dual agonist
Expert: Dual agonist of GLP-1 and GIP receptors, providing synergistic effects on glucose homeostasis, appetite suppression, and weight loss through central and peripheral mechanisms.
Everyday: Mimics two gut hormones that regulate appetite and blood sugar. Helps people feel full and improves how the body processes sugar.
Targets: ["GLP-1","GIP"]
Revenue History
| Period | Revenue ($M) |
|---|
| Q3 2024 | $1,300M |
| 2024 | $4,500M |
Programs (3)
| Indication | Stage | Key Study | Regional Status |
|---|
| Obesity | APPROVED | SURMOUNT-1/2/3/4 | [{"stage":"APPROVED","region":"US","approval_date":"2023-11-08"},{"stage":"APPRO |
| OSA | APPROVED | SURMOUNT-OSA | [{"stage":"APPROVED","region":"US","approval_date":"2024-12-20"}] |
| MASH | PHASE3 | SYNERGY-NASH | [] |
Upcoming Catalysts (3)
Tirzepatide - MASH - Ph3 - Topline (SYNERGY-NASH)
2026
Zepbound - Medicare Part D Access
July 1, 2026
Zepbound vs CagriSema - Obesity - Ph3 - Topline (REDEFINE-4)
H2 2026
Notes
Obesity indication for tirzepatide. Same molecule as Mounjaro.
Data from Supabase · Updated 2026-03-24